The etiology of fulminant non-A, non-B hepatitis has remained unclear, even after the identification of hepatitis C and E viruses. To study the possible involvement of hepatitis B, C, D, and E virus infections, viral genomes were amplified by a sensitive polymerase chain reaction method in sera and liver tissues obtained from 20 patients serologically diagnosed with non-A, non-B fulminant hepatitis (n Å 14), acute hepatitis severe type (n Å 2), and ordinary acute hepatitis (n Å 4). Hepatitis C or E virus RNA could not be detected in sera obtained at admission from these patients. Hepatitis B virus DNA was detected in sera from 3 patients with fulminant hepatitis and in liver from 9 patients with fulminant hepatitis or acute hepatitis severe type. These results suggest that HCV might not be involved in fulminant non-A, non-B hepatitis, and HBV might be related to some of the serologic ''non-A, non-B'' viral hepatitis cases in Japan.
Fulminant hepatitis (FH) is a most severe form of acute liver infectious potential of such HBsAg-negative sera has also been established in chimpanzee transmission experiments [18, 20] . injury, and its outcome is often fatal. Thus far, its etiology has been examined by conventional serologic tests. The discoveries If such HBV infection leads to FH, it must be classified as non-B hepatitis according to classic serologic tests. of hepatitis C virus (HCV) [1] and hepatitis E virus (HEV) [2] have enabled the development of sensitive serologic detection
Here we report the prevalences of HBV DNA, HCV RNA, hepatitis D virus (HDV) RNA, and HEV RNA in non-A, nonmethods [3, 4] . It was shown that most cases of chronic non-A, non-B hepatitis were due to HCV infection [3] . Concerning B FH as well as in severe and ordinary acute hepatitis, based on the detection and analysis of the viral genomes. acute HCV infection, we and others have reported that it is difficult to detect antibody to HCV in the early phase, and therefore nucleic acid detection methods might be required for diagnosing acute HCV infection [5, 6] . However, in regard to Materials and Methods fulminant non-A, non-B hepatitis, the etiology has remained an By applying molecular techniques, Yanagi et al. [7] reported University Hospital between January 1986 and June 1995. FH was that HCV was involved in 43% of fulminant non-A, non-B diagnosed if patients developed hepatic encephalopathy of grade hepatitis in Japan. Subsequently, data suggesting the possible II or more within 8 weeks of the onset of jaundice according to role of HCV in fulminant non-A, non-B hepatitis were docupublished criteria [23] . Patients who showed a plasma prothrombin mented [8, 9] . On the other hand, reports from the United States level of õ40% without developing hepatic encephalopathy were [10 -13] and Europe [14 -17] have shown that HCV might not diagnosed as AH- ST. be involved in fulminant non-A, non-B hepatitis. Thus, the role Among these 36 patients, we selected 20 patients (14 with FH, 2 with AH-ST, and 4 with AH) whose sera and liver samples had of HCV in fulminant non-A, non-B hepatitis remains controverbeen stored suitably for analyzing viral nucleic acids (table 1). sial.
They were all negative for HBsAg, anti-HBc IgM, and antibody Previous studies have shown that hepatitis B virus (HBV) to hepatitis A virus (anti-HAV) IgM. They were also negative for might have caused ''atypical'' hepatitis, in which patients are IgM antibody to cytomegalovirus and to Epstein-Barr virus capsid negative for HBV surface antigen (HBsAg) and antibody to antigen, anti-nuclear antibody, anti-smooth muscle antibody, and HBV core antigen (anti-HBc) of the IgM class [18 -22] . The anti-mitochondrial antibody. None of the patients had evidence of preexisting liver disease or exposure to hepatotoxic drugs.
We also examined HBV DNA in sera and liver tissues from 20 chronic type C hepatitis patients who were negative for HBsAg biopsy from surviving patients and from autopsy cases were frozen RNA extraction from the liver. Total RNA was extracted from 20 mg of frozen liver tissue by using TRIzol reagent (Gibco BRL, immediately and stored at 080ЊC.
Rockville, MD) according to the instructions of the manufacturer. Serologic examination. HBsAg, anti-HBs IgG, anti-HBc IgM, After washing with 75% ethanol and drying, RNA was resusand anti-HBc IgG were examined by RIA (Dinabot, Tokyo), secpended in 50 mL of sterile diethyl pyrocarbonate-treated water. ond-generation anti-HCV antibody (Abbott Laboratories, Abbott
The RNA concentration of the solution was then determined by Park, IL) and IgM antibody to cytomegalovirus were examined spectrophotometer. Between 8 and 10 mg of total RNA was obby EIA, and antinuclear antibody, anti-smooth muscle antibody, tained from each sample. anti-mitochondrial antibody, and IgM antibody to Epstein-Barr virus were examined by a fluorescence antibody method using
Reverse transcription-polymerase chain reaction (RT-PCR) for detecting HCV, HDV, and HEV RNA in sera. Fifty microliters serum samples at admission.
of RNA solution was used for the RT-PCR assay. The primers for Nucleic acid extraction from serum. One hundred microliters detection of each viral genome are shown in figure 1 . RT was of serum was diluted with 500 mL of chaos buffer (50% guanidine done for 30 min at 42ЊC in a 100-mL reaction mixture containing thiocyanate, 0.5% sodium N-lauroylsarcosine, 25 mM Tris-Cl, pH 100 pmol of each outer primer corresponding to each viral se-8.0), followed by extraction with phenol-chloroform (1:1) twice quence (figure 1), 20 mM Tris-Cl, pH 8.3, 50 mM KCl, 2.5 mM and chloroform once and precipitation with ethanol. After washing MgCl 2 , 0.8 mM dNTPs, 18 U of Rous-associated virus-2 reverse with 75% ethanol and drying, nucleic acid was resuspended in 100 transcriptase (Takara Shuzo, Kyoto, Japan), and 110 U of RNase mL of TE buffer (10 mM Tris-Cl, 1 mM EDTA, pH 8.0) for DNA inhibitor (Takara Shuzo). After this step, nested PCR using 2.5 U and 100 mL of sterile diethyl pyrocarbonate-treated water for of Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT) was done. RNA.
Each cycle of PCR consisted of thermal denaturation at 94ЊC (1 DNA extraction from the liver. Twenty milligrams of frozen min), primer annealing at 55ЊC (1 min), and extension at 72ЊC (1 liver tissue was homogenized with TNE buffer (10 mM Tris-Cl, min), all carried out in an automated thermal cycler (Iwaki Glass, pH 7.4, 10 mM NaCl, 2 mM EDTA) and incubated overnight at Chiba, Japan). During the last cycle, extension time was increased 37ЊC with 2% SDS and 400 mg of proteinase K, followed by by an additional 4 min. Thirty-five cycles were done in the first extraction with phenol once, with phenol-chloroform (1:1) twice, round. The first PCR product (2 mL) was then applied to the second and with chloroform once and then precipitation with ethanol.
round of amplification with each inner primer set (figure 1). ThirtyAfter washing with 75% ethanol and drying, DNA was resusfive cycles were done in the second round. Second PCR products pended in 40 mL of TE buffer (pH 8.0). The DNA concentration of the solution was then determined by spectrophotometer.
(10 mL) were analyzed by 8% PAGE and staining with ethidium bromide. To avoid contamination of samples, the extraction and values for the dilution at the point of becoming positive for HBV DNA by the assay were used to quantify the amount of HBV DNA amplification steps were done in separate laboratories, and negative and positive controls were included in each step. The amplified in serum.
Southern blot analysis for PCR products for HBV DNA sequence regions of each viral genome are schematically shown in figure 2 .
The sensitivity of RT-PCR for detecting HCV RNA was examin the liver. Five micrograms of DNA was used for PCR amplification as described above. Multiple primers covering different ined by using the HCV RNA fragment generated from the plasmid containing the HCV genome sequence by in vitro transcription regions of the HBV genome (pre-S, S, core, X; figure 1) of subtype adr [27] were used in the PCR assay for detection of HBV in the [24] . The HCV RNA fragment diluted to an equivalent of 1-1000 copies was added to the control serum, and nucleic acids extracted liver. The locations of these primers are shown in figure 3 . Second PCR product (10 mL) was electrophoresed on a 3% NuSieve 3:1 from those sera were used in the RT-PCR assay. The HCV RNA fragment equivalent to 10 copies was constantly detected, so the agarose gel (FMC, Rockland, ME), stained with ethidium bromide, and photographed under UV light. The separated PCR products sensitivity of our PCR assay for detection of HCV RNA was considered to be §10 copies per specimen.
were denatured by soaking the gel twice in 0.5 M sodium hydroxide-1.5 M sodium chloride for 15 min each and neutralized by The sensitivity of RT-PCR for detecting HDV RNA and HEV RNA was also examined by the same procedure as described soaking twice in 0.5 M Tris-Cl, pH 7.5, and 1.5 M sodium chloride for 15 min each. DNA was transferred to Hybond-N/ nylon transabove. The HDV RNA or HEV RNA fragment was generated from the plasmid containing the HDV genome sequence [25] or fer membrane (Amersham, Amersham, UK). Hybridization was done with Rapid hybridization buffer (Amersham). The filters were HEV genome sequence (gift of G. Reyes [2] ), respectively. Both RNA fragments equivalent to 10 copies were constantly detected, prehybridized for 15 min at 65ЊC and hybridized for 2 h at 65ЊC with 32 P-labeled whole HBV DNA clone (subtype adr). The memso the sensitivity of our PCR assay for the detection of HDV RNA and HEV RNA was considered to be §10 copies per specimen.
branes were washed twice at room temperature in a buffer containing 0.1% SDS-21 SSC (11 SSC is 0.15 M sodium chloride PCR for detecting HBV DNA in sera. Fifty microliters of DNA solution was used for the nested PCR assay for detection of HBV and 15 mM sodium citrate, pH 7.0) for 10 min each, once at 37ЊC in a buffer containing 0.5% SDS-0.11 SSC for 30 min, and twice DNA. The first round of PCR was done using each outer primer set for the surface or core gene (figure 1). First PCR product (2 at 60ЊC in the same buffer for 30 min each. The filters were then exposed to autoradiographic film (Kodak, Tokyo) at 070ЊC with mL) was applied to the second round of amplification with each inner primer set (either surface or core gene) (figure 1); 10 mL intensifying screens and developed. Sequence analysis. For sequence analysis, nested PCR for defrom the second PCR products was analyzed by 8% PAGE and staining with ethidium bromide.
tection of pre-S, surface, and X regions of HBV DNA was done using other sets of primers: PS0, S2B (5-ATTGAGAGAAGTThe sensitivity of our PCR assay for detection of HBV DNA was assessed by using the cloned HBV DNA [26] diluted to an CCACCACG-3; nt 147-128), PS1 (5-GGGTCACCATATTCT-TGGGA-3; nt 2688-2707), and S1B for the pre-S region; S1, equivalent of 0.1-1000 copies per sample and added to 100 mL of serum, and nucleic acids extracted from those sera as described S7B, and S5 for the surface region; and X2, C2B, X7, and X2B for the X region. From 15 mL of the second PCR products, ampliabove were used in the PCR assay. HBV DNA equivalent to 5 copies was constantly detected, so the sensitivity for HBV DNA fied DNA was recovered from 1.5% NuSieve GTG agarose gels (FMC) after electrophoresis on a Magic PCR Preps DNA purificawas considered to be §5 copies per specimen.
The HBV DNA was semiquantitatively determined by diluting tion column (Promega, Madison, WI) according to the instructions of the manufacturer. The purified DNAs were then sequenced the original serum from 1 to 1000 and performing PCR. Reciprocal was added to the solution, and they were used in the RT-PCR assay. The HBV RNA fragment equivalent to 10 copies was constantly detected, so the sensitivity of our PCR assay for detection of HBV RNA was considered to be §10 copies per specimen.
Immunohistostaining of HBV core antigen (HBcAg) in liver tissue. After deparaffinizing and rehydrating, the liver sections were incubated in 3% H 2 O 2 and 10% egg albumin before incubation with primary antibody (rabbit anti-HBc) followed by the second antibody (biotinized anti-rabbit IgG). Vectastain ABC kits (Vector Laboratories, Burlingame, CA) were used for the linking and labeling steps of the immunoperoxidase procedure. The slides were developed in diaminobenzidine, dehydrated, and coverslipped. All washes were done with PBS, and all incubations were done at room temperature.
Results

Serologic examination.
The results of serologic examination for each patient are shown in table 1. All were negative for HBsAg, anti-HBc IgM, anti-HAV IgM, and anti-HCV antibody. The patients positive for anti-HBc IgG were also positive for anti-HBs IgG, and 7 of 14 FH, 2 of 2 AH-ST, and 0 of 4 AH patients were positive for these antibodies (table 1) .
Detection of HCV RNA and HEV RNA in sera. Sera from patients with serologically acute non-A, non-B hepatitis were analyzed for the prevalence of circulating HCV RNA or HEV RNA by RT -nested PCR. Neither HCV RNA nor HEV RNA was detected in any of the 14 pretreatment serum samples from / 9d4c$$au01 07-01-98 21:52:08 jinfa UC: J Infect products, this mutant was also revealed to coexist with the virus without the deletion (data not shown). We were also able to obtain the partial sequence of the X region (nt 1538 -1646) HDV RNA was also examined by RT-PCR in serum samples by direct sequencing in 1 (patient 1) of the 4 FH patients who from patients who were positive for HBV DNA, but it was not were positive for HBV X with Southern blot analysis. The detected in any of them.
sequence was the same as that of the wild type of the X gene Detection of HBV DNA in the liver. Next, we examined of subtype adr [27] (data not shown). HBV DNA by nested PCR in liver tissue to clarify the possible Detection of HBV RNA in the liver. To characterize the correlation with serum HBV DNA. Four different regions of HBV status in non-A, non-B FH, we tried to detect HBV the HBV genome (pre-S, S, core, X) were analyzed (table 3) . transcripts in the liver by RT-PCR assay using primers covering HBV DNA was detected in 7 of the 14 patients with FH (nos.
surface and X regions of HBV. Twelve autopsy samples from 1, 2, 4, 5, 6, 9, 10), in both patients AH-ST (nos. 15, 16) , and FH patients were examined, but HBV RNA could not be dein no patients with AH. In total, 9 (45%) of 20 patients were tected in any liver samples examined (table 2) . positive for HBV DNA in the liver. Figure 4 shows the results
Detection of HBcAg in the liver.
To analyze the expression of Southern blot hybridization after nested PCR for detection of HBcAg in liver tissue, we performed immunohistostaining of various regions of the HBV genome in patient 1 (FH). All for HBcAg. HBcAg was immunostained in the liver from HBV four regions examined were positive for HBV DNA in this carrier patients, but we could not detect HBcAg in any liver patient, but in the other 8 patients, only parts of the HBV tissues from FH and AH-ST patients who were positive for genome were detected (table 3) .
HBV DNA as determined by nested PCR (data not shown). HBV DNA in the liver from 20 patients with chronic type C hepatitis with or without HBV seromarkers was also examined. HBV DNA could not be detected in any liver tissues from 10 Discussion patients without HBV seromarkers. Of 10 patients positive for anti-HBs IgG and anti-HBc IgG, HBV DNA was detected in FH has a poor prognosis despite the fact that patients undergo intensive treatment. It is well-known that HAV, HBV, and 2 (20%) at the core region and in 4 (40%) at the surface region (table 3) .
HDV are associated with FH. The etiologies of acute liver 
/ 9d4c$$au01
07-01-98 21:52:08 jinfa UC: J Infect transfusion hepatitis. In that study, a retrospective survey, 2566 transfused patients were followed at our hospital from 1982 to 1990, but none of the 231 patients with posttransfusion hepatitis developed FH. On the basis of these results, we consider it unlikely for HCV to be the major cause of fulminant non-A, non-B hepatitis. In contrast to the results from pretreatment serum, 4 of 10 patients with FH or AH-ST were seropositive for HCV RNA after treatment with blood products. However, this does not necessarily mean that HCV is the cause of fulminant non-A, non-B hepatitis. In Japan, as a common practice, most patients with FH are given plasma exchange treatment using large amounts of blood products, sometimes up to 100 L. Thus, anti-HCV antibody and HCV RNA could easily have contaminated these products before the Japan Red Cross introduced screening with second-generation anti-HCV antibody in 1992. Therefore, we think such positivity for HCV RNA must have been the consequence of the treatment. We have recently demonstrated that GB virus C, which is considered to be genetically related to HCV and had been considered a causative agent of FH, was not detected in a single patient with FH in injury have thus far been examined on the basis of serologic tests. Regarding the etiology of fulminant viral hepatitis in Japan, it was reported that HAV was involved in 8% and HBV in 47%, but the etiology of the remaining 45%, based on immunologic and serologic analyses, remained unknown [29] . The genome sequences of hepatitis viruses have now been disclosed, and delicate molecular biologic detection methods have become available. As the serologic status might be influenced by the severe biologic reactions in FH cases, we examined the etiology of the so-called non-A, non-B FH in our patient population by nucleic acid amplification methods.
As for HCV involvement in FH, evidence is conflicting; reports from the United States [10 -13] and Europe [14 -17] have shown that HCV might not be involved in sporadic fulminant non-A, non-B hepatitis, while reports from Japan and Taiwan have shown nearly half of the fulminant non-A, non-B hepatitis patients to be positive for HCV RNA [7 -9] . In the current study, we could not detect HCV RNA in any sera taken at admission from patients with FH. Before the identification 1, 2, and 5). Consensus amino acid sequences (top rows) and numbers [31] also reported the prospective assessment of donor blood above sequences are according to subtype adr [27] . ///, deletion; -, identity with consensus sequence.
screening for antibody to HCV as a means of preventing post-/ 9d4c$$au01 07-01-98 21:52:08 jinfa UC: J Infect pretreatment sera but was detected after the administration of the majority of the hepatocytes in these samples had fallen into severe necrosis or apoptosis due to the original disease, so we large amounts of blood products, similar to the results of HCV RNA in this study [32] .
have to be careful in interpreting the results on HBV RNA obtained from these samples. It is known that HEV causes AH in areas in which it is endemic [33] , but in the present study, HEV RNA was detected in none
We do not know the reason why HBV DNA could be detected in FH patients negative for HBsAg and anti-HBc IgM. of the patients. In Japan, HEV is not endemic, and none of our patients had a history of visiting such areas in which it is endemic, One possible explanation for the seronegativity of HBsAg is the low level of HBV replication. In fact, we hardly detected and thus our non-A, non-B hepatitis patients had little chance of being infected with HEV. Accordingly, it is not surprising that HBV DNA in serum and liver with the one-step PCR method, consistent with other reports [10, 14, 42] . In addition, we could none of our patients showed any evidence of infection with HEV. It seems that HEV is also unlikely to be a major etiologic agent not detect HBcAg in the liver by immunohistologic examination, a less sensitive method than the molecular biologic detecfor fulminant non-A, non-B hepatitis in Japanese patients.
Previous studies have demonstrated the presence of HBV tion systems. Another explanation could be found in the mutations in the coding regions of the HBV genome. It was reported infections in serologically diagnosed non-A, non-B chronic hepatitis [34 -38] and FH [10, 14, 39 -42] . In the current study, that a single mutation at the common ''a'' determinant of HBsAg caused a change in the immunologic epitope [28, 46], 3 (21%) of 14 patients were seropositive for HBV DNA and 7 (50%) of 14 patients with fulminant ''non-A, non-B'' hepatiand mutations in the pre-S region led to the inhibition of secretion of the envelope protein [47, 48] . In addition, mutations in tis were positive for HBV DNA in the liver. Thus, it was revealed that HBV DNA was frequently detectable in so-called the precore region have also been suggested to induce AH in patients negative for anti-HBc IgM [18] . Recently, it was renon-A, non-B FH.
The detection of HBV DNA in fulminant non-A, non-B ported that an 8-nt deletion in the X region (corresponding to nt 1642 -1649) might suppress replication and expression of hepatitis might suggest that HBV is involved in its pathogenesis. However, this evidence may be insufficient to confirm a HBV DNA, and it seems to be responsible for the absence of serologic markers despite the presence of HBV infection [22] . direct correlation between HBV and fulminant non-A, non-B hepatitis. It has been reported that HBV DNA is detectable by
In view of these observations, we tried to identify the region of the viral genome that might be responsible for the lack of a sensitive PCR method in patients with previous HBV infection [34] , so we also examined chronic type C hepatitis patients production of HBsAg. As shown in figure 5 , we could obtain nucleotide sequences responsible for HBsAg in 3 patients in with comparable HBV seromarkers. In the control study, we could not detect HBV DNA in the serum or liver from patients this analysis. However, we could not find any mutation in the common ''a'' determinant in these 3 patients. In addition, we without HBV seromarkers, but we could detect HBV DNA in the liver from some patients possessing HBV seromarkers.
could obtain the partial sequence of X region for 1 patient, and the sequence revealed the wild type of the HBV X gene of Thus, as for the FH cases without any HBV seromarkers, the detection of HBV DNA might mean the possible involvement of subtype adr [27] . The specific deletion of 8 nt in the X region of HBV reported to be present in HBsAg-seronegative AH HBV as an etiologic agent. Actually, Lugassy et al. [39] and Chazouilleres et al. [41] have already demonstrated the existence patients by Uchida et al. [22] was not found in this case. The specific mutations in the core promoter region observed in 72% of ''occult'' HBV DNA in the liver or sera from patients with FH who had been negative for serologic HBV markers.
of type B FH patients in Japan [49] , in 10% in the United States [50] , and in 38% in Europe [51] were not found in this Our control study indicated that the detection of HBV DNA in the liver with HBV seromarkers might reflect the evidence case. To further clarify this, we will need to obtain the full nucleic acid sequences of these viruses. of past HBV infection. However, in HBV-induced FH, it was previously described that an unusually strong and rapid immune
We also examined the possible HDV involvement in those patients who were positive for HBV DNA, but HDV RNA clearance of HBsAg and enhanced production of anti-HBs might be involved in its pathogenesis [43] [44] [45] . Such mechanism might could not be detected in any of them. The etiologic agent of sporadic acute non-A, non-B viral contribute to the results that anti-HBs was detected in patients with FH or severe AH caused by HBV. Thus, there still remains hepatitis has remained obscure. Serologic assay systems have limitations because they are based on the immunologic rea possibility that HBV caused the FH in patients who were positive for both HBV DNA and anti-HBs or anti-HBc IgG.
sponse by the host. Therefore, sensitive molecular diagnostic systems, such as the PCR method, are required to examine the To further assess the HBV status in the liver, we used RT-PCR assay to detect HBV RNA in liver samples from 12 FH presence of such an infectious agent. By applying the sensitive PCR method, we have shown that HCV had little involvement patients. However, we could not detect HBV RNA in any liver samples examined. The lack of detection of HBV RNA in the etiology of fatal FH, at least in our patient population in the Chiba area, as well as the existence of HBV DNA in suggests that active replication of HBV was not occurring at the time of collection of these samples. However, the liver some of the patients in whom we could not diagnose HBV infection by conventional serologic assay. tissues examined for HBV RNA were all autopsy samples, and
